Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5351_Библиотеки_им_академика_М_И_Перельмана.pdf
Parenteral products CHAPTER 38
Non-aqueous solvents
Water-miscible cosolvents, such as glycerin and propylene glycol, are used as vehicles in small-volume
parenteral fluids. They are used to increase the solubility of drugs and to stabilize drugs degraded by
hydrolysis.
Metabolizable oils are used to dissolve drugs that
are insoluble in water. For example steroids, hormones and vitamins are dissolved in vegetable oils.
These formulations are administered by intramuscular injection.
Additives
Various additives, such as antimicrobial agents, antioxidants, buffers, chelating agents and tonicityadjusting agents, are included in injection formulations. Their purpose is to produce a safe and elegant
product. Both the types and amounts of additives to
be included in formulations are given in the appropriate monograph in the BP (2007).
Antimicrobial agents
These are added to products that are packaged in
multiple-dose vials. They are not used in largevolume injections or if the drug formulation itself
has sufficient antimicrobial activity (such as Methohexital Sodium Injection). Antimicrobial agents
are added to inhibit the growth of microbial organisms that may accidentally contaminate the product
during use. The antimicrobial agents must be stable
and effective in the parenteral formulation. Because
they are effective in the free form, their activity can
be greatly reduced by interaction with components
of the injection. Rubber closures have been shown
to take up antimicrobial preservatives from the injection solution. Preservative uptake is m ore significant with natural and neoprene rubber and much
less with butyl r ubber closures.
There is concern about the toxic eff ects of injections containing preservatives. As a result, a low but
effective antimicrobial concentration is used in
injections. Challenging the product with selected
organisms can test the effectiveness of antimicrobial agents. The test procedure will evaluate the antimicrobial activity of the preservative in the
packaged product. The test procedure is detailed
in BP 2007. Ta ble 38.1 gives details for some com-
monly used preservatives.
Table 38.1 Examples of antimicrobial preservatives used in
aqueous multiple dose injections
Antimicrobial preservative Concentration (% w/v)
Benzyl alcohol 1–2
Chlorocresol 0.1–0.3
Cresol 0.25–0.5
Methyl hydroxybenzoate 0.1
Phenol 0.25–0.6
Thiomersal 0.01
Antioxidants
Many drugs in aqueous solutions are easily degraded by
oxidation. Small-volume parenteral products of these
drugs often contain an antioxidant. Bisulphites and metabisulphites are commonly used antioxidants in aqueous
injections. Antioxidants must be carefully selected for
use in injections to avoid interaction with the drug. Antioxidants have a lower oxidation potential than the drug
and so are either preferentially oxidized or block oxidative chain reactions. Injection formulations may, in addition to antioxidants, also contain chelating agents.
Chelating agents such as EDTA or citric acid remove
trace elements which catalyse oxidative degradation.
Buffers
The ideal pH of parenteral products is pH 7.4. If the
pH is above pH 9, tissue necrosis may result, while
below pH 3, pain and phlebitis in tissues can occur.
Buffers are included in injections to maintain the
pH of the packaged product. Changes in pH can arise
through interaction between the product and the container. However, the buffer used in the injection must
allow the body fluids to change the product pH after
injection. Acetate, citrate and phosphate buffers are
commonly used in parenteral products.
Tonicity-adjusting agents
Isotonic solutions have the same osmotic pressure as
blood plasma and do not damage the membrane of red
blood cells. Hypotonic solutions have a lower osmotic
pressure than blood plasma and cause blood cells to
swell and burst because of fluids passing into the cells
by osmosis. Hypertonic solutions have a higher osmotic pressure than plasma; as a result the red blood
cells lose fluids and shrink. Following the administration of an injection it is important that tissue damage
419
SECTION FOUR Dispensing and related pharmaceutical practice activities
and irritation are minimized and haemolysis of red
blood cells is minimized. Thus, the BP (2007) states
that aqueous solutions for large-volume infusion
fluids, together with aqueous fluids for subcutaneous,
intradermal and intramuscular administration, should
be made isotonic. Intrathecal injections must also be
isotonic to avoid serious changes in the osmotic pressure of the cerebrospinal fluid. Aqueous hypotonic
solutions are made isotonic by adding either sodium
chloride, glucose or, occasionally, mannitol. The latter
two agents are incompatible with some drugs. If the
solution is hypertonic, it is made isotonic by dilution.
Some components of injections, such as buffers
and antioxidants, affect the tonicity. Other components, such as preservatives, which are present in
low concentration, have little effect on the tonicity.
Injection solutions are often made isotonic with
0.9% sodium chloride solution. The amount of solute, or the required dilution necessary to make a
solution isotonic, can be determined from the
freezing point depression. The freezing point depression of blood plasma and tears is 0.52
Thus solutions that freeze at 0.52
Chavethe
C.
same osmotic pressure as body fluids. Hypotonic
solutions have a smaller freezing point depression
and r equire the addition of a solute to depress the
freezing point to 0.52
C.
The amount of adjusting substance added to these
solutions may be calculated from the equation:
W ¼ð0:52 aÞ=b
where W = percentage concentration of adjusting
substance in the final solution, a = freezing point
depression of the unadjusted hypotonic solution,
b = freezing point depression of a 1% weight in volume (w/v) concentration of the adjusting substance.
An extensive list of freezing point depression
values is detailed in Table 6 (pp 53–64) in the chapter
‘Solution properties’ in the 12th edition of the Phar-
maceutical Codex (1994) (Example 38.1).
Other methods that are used to estimate the
amount of adjusting substances required to make a
solution isotonic include:
*
Sodium chloride equivalents
*
Molar concentrations
*
Serum osmolarity.
Details of these methods are given in the chapter
‘Solution properties’ (pp 64–67) in the 12th edition
of the Pharmaceutical Codex (1994).
Units of concentration
The concentration of the components in parenteral
products may be expressed in various ways (see also
Ch. 26):
*
Percentage weight/volume. Examples include:
magnesium sulphate injection 50%, sodium
chloride intravenous infusion 0.9%.
*
Weight per unit volume. Examples include: atropine
sulphate 600 micrograms/mL or ephedrine
hydrochloride injection 30 mg/mL.
*
Millimoles per unit volume. Examples include:
potassium chloride solution, strong (sterile)
contains 2 mmol each of K
Calcium Chloride Injection BP contains 2.5 mmol
2+
of Ca
and 10 mmol of Clin 5 mL.
During the formulation of injections and infusions,
the units of interest are the ions of electrolytes and
the molecules of non-electrolytes. For molecules,
1 millimole (mmol) is the weight in milligrams corresponding to its relative molecular mass. A mole of an
ion is its relative atomic mass weighed in grams. The
number of moles of each of the ions of a salt in solution depends on the number of each ion in the molecule of the salt (Example 38.2).
+
and Clper mL;
Example 38.1
A 100 mL volume of a 2% w/v solution of glucose for
intravenous injection is to be made isotonic by the
addition of sodium chloride.
A 1% w/v solution of glucose depresses the freezing point
of water by 0.1
depresses the freezing point of water by 0.576
The depression of freezing point of the unadjusted solution
of glucose (a) will therefore be:
420
C and a 1% solution of sodium chloride
ðaÞ¼2 0:1 ¼ 0:2
C.
A 1% w/v solution of sodium chloride depresses the
freezing point of water by 0.576
Substituting these values for a and b in the above
equation:
W ¼ð0:52 0:2Þ=0:576 ¼ 0:32=0:576 ¼ 0:555
The intravenous solution thus requires the addition of
0.555 g of sodium chloride per 100 mL volume to make it
isotonic with blood plasma.
C(b).
Example 38.2
Sodium chloride has one sodium and one chloride ion.
Thus, 1 mole of sodium chloride provides 1 mole of both
sodium and chloride ions. The weight of sodium chloride
which provides a 1 mmol quantity is 58.5 mg. This weight
corresponds to its relative molecular mass and provides
1 mmol of both sodium and chloride ions.
Magnesium chloride has one magnesium and two chloride
ions. The weight in milligrams that provides 1 mmol of
magnesium and 2 mmol of chloride ions is 203 mg. This
Example 38.3
Calculate the quantities of salts required for the following
electrolyte solution:
Sodium 12 mmol
Potassium 4 mmol
Magnesium 6 mmol
Calcium 6 mmol
Chloride 40 mmol
Water for injections to 1 L
From Table 4 in the Pharmaceutical Codex (1994), 4 mmol
of potassium ion is provided by 4 74.5 mg of potassium
chloride, which also yields 4 mmol of chloride ions.
Parenteral products CHAPTER 38
weight corresponds to the relative molecular mass of this
salt. The quantity of salt in milligrams containing 1 mmol of
a particular ion can be determined by dividing the relative
molecular mass of the salt by the number of the particular
ions that it contains. Weights of common salts that provide
1 mmol are given in Table 4 in the chapter ‘Solution
properties’ (pp 49–50) in the 12th edition of the
Pharmaceutical Codex (1994).
6 mmol of magnesium ions is provided by 6 203 mg of
magnesium chloride, which also yields 2 6 = 12 mmol of
chloride ions as there are two chloride ions in the molecule.
6 mmol of calcium ions is provided by 6 147 mg of
calcium chloride, which also yields 12 mmol of chloride
ions as there are two chloride ions in the molecule.
12 mmol of sodium ions is provided by 12 58.5 mg of
sodium chloride that also yields 12 mmol of chloride. The
formula can, therefore, be shown as in Table 38.2. It should
be noted that the charges on the anions and cations are
equally balanced.
Table 38.2 The formula for Example 38.3
Na
+
K
+
Millimoles of
2+
Mg
Ca
2+
Sodium chloride 12 58.5 = 0.702 g 12 12
Potassium chloride 4 74.5 = 0.298 g 4 4
Magnesium chloride 6 203 = 1.218 g 6 12
Calcium chloride 6 147 = 0.882 g 6 12
Water for injections to 1 L
Total (mmol/L) 12 4 6 6 40
Conversion equations
Useful conversion equations include the following:
mg per litre = W M
where W = the number of milligrams of salt containing 1 mmol of the required ion, M = the number of
millimoles per litre (Examples 38.3–38.5).
Special injections
grams per litre = (W M)/1000
% w/v = (W M)/10 000
These are more complex formulations than solutions
for injection.
Cl
421
SECTION FOUR Dispensing and related pharmaceutical practice activities
Example 38.4
Calculate the number of millimoles of dextrose and
sodium ions in 1 litre of sodium chloride and dextrose
injection containing 5% anhydrous dextrose and 0.9%
w/v of sodium chloride.
Use the conversion equation for % w/v calculations:
%w=v ¼ðW=MÞ10 000
From this equation:
M ¼ % w=v 10 000=W
For dextrose
As dextrose is a non-electrolyte, W = 180.2. Thus:
M ¼ 5:0 10 000=180:2 ¼ 277 mmol
The 1 litre of solution contains 277 mmol.
For sodium chloride
M ¼ 0:09 10 000=58:5 ¼ 15:4 mmol
As 1 mmol of sodium chloride provides 1 mmol of both
sodium and chloride ions, 1 litre of the solution will contain
15.4 mmol of both sodium and chloride ions.
Example 38.5
Calculate the number of millimoles of magnesium and
chloride ions in 1 litre of a 2% solution of magnesium
chloride.
M ¼ 0:2 10 000=203 ¼ 9:85
Each mole of magnesium chloride provides 1 mole of
magnesium ions and 2 moles of chloride ions. Thus, 1 litre
of the solution contains 9.85 mmol of magnesium ions and
19.7 mmol of chloride ions.
Suspensions
Commonly, suspensions for injection contain less
than 5% of drug solids with a mean particle diameter within the range 5–10 mm. Owing to the presence of particles in these formulations, these
injections are more difficult to process and sterilize
than solutions for inj ection. During the manufacture of suspensions for injection, the components
are prepared and sterilized separately. They are
then aseptically combined (see Ch. 29). The final
product cannot be filter sterilized owing to the
presence of particles in the formulation. Powders
for use in sterile suspensions can be sterilized by
gas, but gas residues m ust be avoided.
Dried injections
With these products the dry sterile powder is aseptically added to a sterile vial. Alternatively, a sterile
filtered solution can be freeze dried in a vial. The dry
drug powder is reconstituted with a sterile vehicle
before use.
Non-aqueous injections
Drugs that are insoluble in an aqueous vehicle can be
formulated in solution using an oil as the vehicle.
These formulations are less common than aqueous
suspensions. Several oils are used in these formulations, including arachis oil and sesame oil, which are
easily metabolized. These viscous injections give a
depot effect with slow release of the drug and are
administered by intramuscular injection.
Large-volume parenteral products
These are parenteral products that are packed and
administered in large volumes. They are formulated
as single-dose injections that are administered by intravenous infusion. They are sterile aqueous solutions
or emulsions with water for injections as the main
component. It is important that they are free of particles. During the administration of these fluids, additional drugs are often added to the fluids (see Ch.
40). This may be carried out by the injection of small-
422
Parenteral products CHAPTER 38
volume parenteral products to the administration set
of the fluid, or by the ‘piggyback’ method. In this
procedure a second, but smaller, volume infusion of
an additional drug is added to the intravenous delivery
system.
Large-volume parenteral products include:
*
Infusion fluids
*
Total parenteral nutrition (TPN) solutions
*
Intravenous antibiotics
*
Patient-controlled analgesia
*
Dialysis fluids
*
Irrigation solutions.
All of these products have direct contact with blood
or are introduced into a body cavity. Large-volume
parenterals are variously formulated and packaged
and have been used to:
*
Restore fluid and electrolyte imbalance in patients
suffering from dehydration, shock or injury
*
Provide nutrition in circumstances where patients
are malnourished, e.g. TPN
*
Act as a vehicle for administration of medicines
*
Perform dialysis
*
Allow irrigation of body parts.
Large-volume parenterals must be terminally heat
sterilized. While water for injections is the main component of these products, they also incorporate other
ingredients including:
*
Carbohydrates, e.g. dextrose, sucrose and dextran
*
Amino acids
*
Lipid emulsions which contain vegetable or
semisynthetic oil
*
Electrolytes such as sodium chloride
*
Polyols, including glycerol, sorbitol and mannitol.
Most large-volume parenteral fluids are clear aqueous
solutions, except for the oil-in-water emulsions. The
production of emulsions for infusion is highly specialized as they are destabilized by heat. This results in
production difficulties, particularly because the size
of the oil droplets must be carefully controlled during
the heat sterilization.
Production of large-volume
parenteral products
The fluids are produced and filled into containers in a
high-standard clean room environment (see Ch. 29).
The high standards are required to limit the contamination of these products with organisms, pyrogens
and particulate matter. Use of stringent quality assurance procedures is essential to ensure the quality of
the products.
In commercial manufacturing facilities, large
volumes of fluids are used in the production of a batch
of product. The fluids are packaged from a bulk container into the product container in highly mechanized operations using high-speed filling machines.
Just before the fluid enters the container, particulate
matter is removed from the fluid by passing it through
an in-line membrane filter. Immediately after filling,
the neck of each glass bottle is sealed with a tightfitting rubber closure that is kept in place with a
crimped aluminium cap. The outer cap is also aluminium and an outer tamper-evident closure is used.
When using plastic bags, the preformed plastic
bag is aseptically filled and immediately heat sealed.
As an alternative, a blow–fill–seal system can be used.
This integrated system involves melting the plastic,
forming the bag, filling and sealing in a high-quality
clean room environment. Blow–fill–seal production
decreases the problems with product handling, cleaning and particulate contamination. Following filling of
the product into containers, the fluids are examined
for particulate matter and the integrity of container
closures established.
Moist heat should be used to sterilize parenteral
products, irrigation solutions and dialysis fluids wherever possible. This should be carried out as soon as
possible after the containers have been filled. Plastic
containers must be sterilized with an over-pressure
during the sterilization cycle to avoid the containers
bursting.
Containers and closures
Large-volume parenteral fluids are packaged into:
*
Glass bottles
*
Polyvinyl chloride (PVC) collapsible bags
*
Semi-rigid polythene containers.
The containers and closures that are used for packaging parenteral products must:
*
Maintain the sterility of the packed fluids
*
Withstand sterilization
*
Be compatible with the packed fluid
*
Allow withdrawal of the contents.
Glass bottles are normally made of Type II glass
(Fig. 38.4), but Type I glass is used for products that
have a high pH, despite the increased costs. Glass
bottles have advantages for packaging these fluids as
423
SECTION FOUR Dispensing and related pharmaceutical practice activities
*
They permit a high moisture penetration
*
They adsorb some drugs
*
They require an extended sterilization time due to
the heat resistance of the PVC
*
Moist heat sterilization requires air ballasting to
avoid pouch explosion.
Semi-rigid plastic containers are used for volumes
of 100 mL for electrolyte solutions, 3 L for TPN solutions and up to 5 L for dialysis solutions.
Semi-rigid containers:
*
Are more drug compatible than PVC containers
*
Are difficult to break
*
Do not fully collapse
*
Need extended heat sterilization times
*
Need air equilibration.
Semi-rigid bags are designed with two ports. One
port allows the attachment of the administration
set. The other port permits the addition of smallvolume parenteral products or small-volume infusion
Figure 38.4*Glass infusion fluid container.
fluids. These containers are intended for single use.
They have a graduated scale that can be read either
in an inverted or upright position (Fig. 38.5). To en-
they are transparent and chemically inert. They may
able containers of large-volume parenterals to be
be used for products that are incompatible with
plastic containers. Glass bottles also have some
disadvantages. They are much heavier than plastic
and therefore less transportable. Although they are
strong, they are also brittle, and subject to damage
during transport and storage. During use they require
the use of an air inlet filter device for pressure equilibration within the container. Particles of glass can be
released into the injection fluids. Damage to the neck
of the bottles may result in contamination of the
container contents from the external environment.
A further problem with glass containers may occur
during moist heat sterilization. This results in contamination of the fluid due to a pressure imbalance
between the internal and external environment. Owing to these difficulties with glass containers, plastic
containers have become widely used.
PVC collapsible bags are used to package most
infusion fluids. They are designed with a port for the
attachment of the administration set and an additive
port for the addition of small-volume parenteral
fluids.
PVC collapsible bags are:
*
Resistant to impact
*
Flexible and collapse during fluid administration
and so do not require an air inlet system.
The disadvantages of plastic bags are:
Figure 38.5*Semi-rigid infusion bag.
424
Parenteral products CHAPTER 38
suspended from a drip stand for administration, bags
are made with an eyelet opening that can be pierced to
suspend the bag. Glass bottles are supplied with a
plastic band that fits around the container to allow
the bottle to be suspended during fluid administration.
Administration of large-volume
parenteral fluids
All large-volume parenterals are administered to the
patient by a parenteral route using a wide variety of
administration sets. Most infusion fluids are administered using the standard infusion set specified in
British Standard 2463 (Part 2, 1989). These sets are
packaged as sterile units intended for single use
(Fig. 38.6). Fluid moves through them by gravity, at
a rate that is affected by the physical characteristics of
the fluid and the fluid pressure, determined by the
height of the infusion above the patient. The administration set is made up of a rigid plastic spike that is
inserted into the rubber septum of an infusion container. A filter that removes any particles from the
fluid is positioned above a clear drip-control chamber,
which aids monitoring the fluid flow rate. These components are connected by at least a 150 cm length of
clear flexible tubing. The tubing has a flow regulator
and a rubber injection port. The tubing is fitted with a
Luer connector for attachment to a needle or catheter
that is inserted into the vein of a patient.
Labelling
Batch-produced products have identical labels attached to both the product and the outer packaging
carton that is used for transport. With flexible plastic
containers, the labelling requirements are commonly
printed directly on to the container prior to filling.
With bags containing TPN fluids, a label is placed on
the bag itself and an identical label is attached to the
outer plastic cover on the bag. Labels are attached to
infusion fluid containers. The labels on parenteral
fluids should include the following details:
*
Product identity and details of the contained
volume
*
Solution strength in terms of the amount of active
ingredient in a suitable dose-volume
*
Batch number and product expiry date
*
Storage requirements
*
For TPN solutions, the name of the patient, the
unit number, ward and infusion rate.
Containers often carry a warning label to discard the
remaining product when treatment is completed.
Figure 38.6*Diagram of a typical administration set. (From BS
2463: Part 2, 1989, reproduced with permission.)
Aseptic dispensing
Most parenteral fluids are terminally moist heat sterilized. However, some products are aseptically compounded from sterile ingredients in the hospital
pharmacy. These products are prepared and dispensed for individual patients. Examples of aseptically prepared products are TPN fluids and the aseptic
reconstitution of freeze-dried formulations. These
freeze-dried products are often reconstituted using
either water for injections or 0.9% sodium chloride
injection. Aseptic dispensing is performed in a Grade
A clean room environment or a Grade A isolator
chamber (see Ch. 40). The dispensing of these products relies on good aseptic procedures to ensure the
sterility of the product. Owing to the absence of terminal sterilization, it is important that manufacture is
performed using rigorous quality assurance procedures. Aseptically dispensed products are given a very
limited expiry time.
425
SECTION FOUR Dispensing and related pharmaceutical practice activities
Infusion fluids used for nutrition
Nutrients can be delivered to patients by intravenous
administration. This is known as total parenteral nutrition and should allow for both tissue synthesis and
anabolism. Some patients require TPN for prolonged
periods. Initially patients are provided with their TPN
in hospital. They may then undergo training to allow
self-administration at home. This is known as home
parenteral nutrition. Information on total and home
parenteral nutrition is given in Chapter 41.
Admixtures
These are prepared by adding at least one sterile injection to an intravenous infusion fluid for administration. The injections to be added are packed in an
ampoule or vial, or may be reconstituted from a solid.
These additions should be carried out using aseptic
procedures in a Grade A environment within an isolator cabinet or clean room facility. This environment
is required to maintain the sterility of the product and
avoid contamination of the product with particulate
matter, microorganisms and pyrogens. Following the
additions, a sealing cap may be placed over the additive port of the infusion bag to prevent further,
potentially incompatible, additions at ward level.
Hospital pharmacies often have a centralized intravenous additive service (CIVAS) as detailed in Chapter
40. These facilities ensure that additions to infusion
fluids are carried out in a suitable environment.
self-administration of medicines by patients requires
careful consideration of several factors including:
*
Delivery volume and control of flow rate
*
Complexity of the administration procedure
*
Type of therapy being administered
*
Frequency of dosing
*
Reservoir volume available in the infusion device.
Infusion devices available include:
*
Infusion pumps and controllers
*
Elastomeric infusers
*
Electromechanical syringe pumps.
All these devices should be:
*
Mechanically reliable with accurate flow rates
*
Able to provide an output pressure which will not
damage the injection site
*
Supported with a back-up power supply if
electrically operated
*
Compact and portable
*
Simple to operate for hospital staff and home care
patients.
Infusion pumps
These devices use pressure as the driving force to
allow administration of fluids into the patient. Infusion pumps, which can be divided into those that
move fluid by a piston and valve mechanism and those
that move the fluid by peristalsis, are widely used.
Infusion pumps are expensive to purchase and operate but allow fluids to be accurately infused into the
patient at a slow rate. These devices are becoming
more sophisticated with greater electronic controls.
Novel delivery systems
Special delivery systems are used to facilitate selfmedication by patients in a home environment. Some
of these delivery systems are described below.
Infusion devices
There are situations that require strict control of the
volume of fluids that are infused into a patient. Accurate flow control with infusion devices is vital for patient safety and for optimum efficacy of the infusion.
A range of delivery systems are available that regulate
the volume of fluid administered to the patient.
These systems are used both in the hospital and
for the self-administration of fluids by patients at
home. The selection of an infusion device for the
426
Infusioncontroller
This is a simple device that can accurately deliver the
required fluid volume, although difficulties occur
with the administration of viscous solutions. The device relies on gravity moving the infusion fluid down
the intravenous administration set. The drop rate in
the administration set drop chamber is monitored by a
photoelectric mechanism. The device then applies a
constriction on the tube of the administration set to
give a preselected flow rate.
Elastomeric infusers
These devices are made of a rigid or flexible outer
shell with an inner flexible reservoir (Fig. 38.7). The
reservoir inside the device is aseptically filled with the
fluid. The elasticity of the filled reservoir exerts a
constant pressure. This forces the fluid through an
Figure 38.7*Elastomeric infuser. (Courtesy of Baxter Health-
care Ltd.)
integrated flow restriction device that controls the
rate of fluid outflow. The tube from the infuser can
be connected to an indwelling cannula in a central vein
of the patient. These devices are expensive but they
are simple to operate and allow easy home care use.
Parenteral products CHAPTER 38
0.9% w/v sodium chloride solution or sterile water for
irrigation. Most irrigation fluids are now available in
rigid plastic bottles. Urological irrigation solutions are
used for surgical procedures; they are usually sterile
water or sterile glycine solutions and are used to remove blood and maintain tissue integrity during an
operation.
Water for irrigation is sterilized distilled water that
is free of pyrogens. The water is packed in containers
and is intended for use on one occasion only. The
containers are sealed and sterilized by moist heat.
Peritoneal dialysis fluids
Peritoneal dialysis involves the administration of dialysis solutions directly into the peritoneum by way of an
indwelling catheter. The fluid is then drained after a
‘dwell-time’ to remove toxic waste products from the
body. Peritoneal dialysis solutions are sterile solutions
manufactured to the same standards as parenteral
fluids. The composition of peritoneal dialysis fluid
simulates potassium-free extracellular fluid. These
fluids are packaged in volumes of 3–5 L in plastic
containers that are similar to the bags used for TPN
(see Ch. 41).
Syringe infusers
These devices are used for controlling the delivery of
small volumes of intravenous infusions over a predetermined period of time. The syringe driver is widely used
as an infusion controller for the administration of intravenous antibiotics and patient-controlled analgesia.
They are often powered by mains electricity, or may
be battery operated, although clockwork syringe infusers have limited low-risk applications. Syringe infusers
move the syringe plunger by a motor-driven screw forcing the fluid into tubing for delivery to the patient.
These small, lightweight devices allow the administration of precise volumes of fluids. Syringe devices provide good patient home care for patient-controlled
analgesia where the drug is often infused over long
periods. Patient-controlled analgesia is used by patients
to self-regulate the intravenous administration of painrelieving drugs at controlled intervals. Parenteral administration gives a rapid onset of drug action.
Irrigation solutions
These solutions are applied topically to bathe open
wounds and body cavities. They are sterile solutions
for single use only. Examples of irrigation fluids are
Haemodialysis
In this dialysis procedure, blood is removed and
returned to the patient by way of a catheter, or a
double needle arrangement, using a fistula where an
artery and vein are joined together. The dialysis procedure involves the use of an artificial disposable
membrane within a ‘dialyser’ machine that acts as
an artificial kidney. An electrolyte fluid, simulating
body fluid, bathes one side of the membrane, with
blood from the patient on the other side. There is no
direct contact between the blood and the dialyser
fluid. Thus fluids for haemodialysis do not require
to be sterile or free of pyrogens or particulate matter.
Fluid volumes of 30–50 L are used daily in haemodialysis procedures (see Ch. 41).
Blood products
These products are not usually identified as sterile
products although they are commonly packaged as
sterile large-volume parenteral fluids. These biological
products include albumin, human plasma and blood
protein fractions. All these products must be treated
427
SECTION FOUR Dispensing and related pharmaceutical practice activities
*
to inactivate virus contamination prior to packaging.
This is usually achieved by specialized heat treatment
or filtration. These products are unstable to heat sterilization. Therefore, they are filter sterilized and then
aseptically filled into containers in large-scale production facilities. Most of these products are packed as
liquids, although a few blood protein fractions such as
factor VIII and factor IX are freeze dried. The collection, management and distribution of these products
is carried out by the blood transfusion service.
KEY POINTS
*
Convention uses the term ‘parenteral’ for dosage
forms which are placed directly into the body
*
The three main routes are subcutaneous,
intramuscular and intravenous, but many others
are used in particular situations
*
Parenteral products are sterile forms used for
injection, infusion or implantation
*
Glass ampoules are convenient for small volumes,
but glass particles can fall into the injection during
opening
*
Multiple-dose injections must have an
antimicrobial preservative
*
Water for injections must be used as the aqueous
ingredient in all injections
*
Water for irrigations is used in large volumes to
irrigate body cavities and other areas
*
Pyrogens cause fever and must be eliminated from
water for injections and water for irrigations
Endotoxins, from Gram-negative bacteria, are a
major type of pyrogen
*
Bacterial endotoxin is detected using the LAL
tests, while pyrogens in general are detected by the
rabbit pyrogen test
*
Additives to injections include antimicrobial
preservatives, antioxidants, buffers, tonicity
adjusters and cosolvents
*
Injection solutions for subcutaneous,
intradermal, intramuscular, intrathecal and
large-volume intravenous use should be made
isotonic
*
Tonicity calculations are normally based on
freezing point depression, but sodium chloride
equivalents, molar concentrations and serum
osmolarity can be used
*
There is a wide range of large-volume parenteral
products, including infusion fluids, total
parenteral nutrition, dialysis fluids and irrigation
solutions
*
All large-volume parenteral products must be
sterilized after filling into their final containers
*
Large-volume parenteral products may be
packaged in glass bottles, semi-rigid or collapsible
plastic containers
*
When aseptic dispensing is required, rigorous
quality assurance is essential and a 1-week expiry
date is given to the product
*
A range of infusion devices is available for hospital
use and to assist patients’ self-administration of
infusions at home
*
Sterile solutions have other uses, such as in
peritoneal dialysis
428